Nebenwirkungen · Onivyde pegylated liposomal (previously Onivyde)
ONIVYDE pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion · Abschnitt 4.8 · PDF-Seite 16
HOS-135490 · Präparat HOS-097714
ONIVYDE pegylated liposomal in combination with 5-fluorouracil and leucovorin: In NAPOLI-1, Grade 3 or Grade 4 diarrhoea occurred in 12.8% receiving ONIVYDE pegylated liposomal +5-FU/LV. For patients experiencing late diarrhoea, the median time to late diarrhoea onset was 8 days from the previous dose of ONIVYDE pegylated liposomal. Early onset diarrhoea, typically appearing ≤ 24 hours after dose administration, can occur and is usually transient. Early onset diarrhoea may also be accompanied by cholinergic symptoms that can include rhinitis, increased salivation, flushing, diaphoresis, bradycardia, miosis and hyperperistalsis that can induce abdominal cramping. Early diarrhoea onset occurred in 29.9% and cholinergic events occurred in 3.4% receiving ONIVYDE pegylated liposomal +5-FU/LV.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-11-29T09:48:00Z · SHA-256 6fe241cd32f9f9d3c8592da7ea124a85ef29388269021487b0409971bc580040 · Passage f99ac828d055ad0974d221c78746dd1fd337f219749674f9309bc043d1df3a54 · Zeichen 18287–19085 im Abschnitt